1204417-25-3

Basic information

• Product Name: 13-cyclohexyl-3-methoxy-6-[[methyl[2-[2-(methylamino)ethoxy]ethyl]amino]carbonyl]-7H-Iindolo[2,1-a][2]benzazepine-10-carboxylic acid, 1,1-dimethylethyl ester
• Synonyms: 13-cyclohexyl-3-methoxy-6-[[methyl[2-[2-(methylamino)ethoxy]ethyl]amino]carbonyl]-7H-Iindolo[2,1-a][2]benzazepine-10-carboxylic acid, 1,1-dimethylethyl ester
• CAS NO: 1204417-25-3
• Molecular Weight: 601.786
• Mol File: 1204417-25-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 13-cyclohexyl-3-methoxy-6-[[methyl[2-[2-(methylamino)ethoxy]ethyl]amino]carbonyl]-7H-Iindolo[2,1-a][2]benzazepine-10-carboxylic acid, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 13-cyclohexyl-3-methoxy-6-[[methyl[2-[2-(methylamino)ethoxy]ethyl]amino]carbonyl]-7H-Iindolo[2,1-a][2]benzazepine-10-carboxylic acid, 1,1-dimethylethyl ester(1204417-25-3)
• EPA Substance Registry System: 13-cyclohexyl-3-methoxy-6-[[methyl[2-[2-(methylamino)ethoxy]ethyl]amino]carbonyl]-7H-Iindolo[2,1-a][2]benzazepine-10-carboxylic acid, 1,1-dimethylethyl ester(1204417-25-3)

Safety Data

• Hazardous Substances Data: 1204417-25-3(Hazardous Substances Data)

Upstream product

• 139962-95-1 2-formyl-4-methoxyphenylboronic acid 
• 879498-90-5 1H-indole-6-carboxylic acid, 2-bromo-3-cyclohexyl-, 1,1-dimethylethyl ester 
• 958002-18-1 1H-indole-6-carboxylic acid, 3-cyclohexyl-2-(2-formyl-4-methoxyphenyl)-, 1,1-dimethylethyl ester 
• 928844-30-8 13-cyclohexyl-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid 10-(1,1-dimethylethyl) ester 6-methyl ester 
• 2620-27-1 1,5-bis(methylamino)-3-oxapentane 
• 1204417-76-4 C₃₁H₃₅NO₅ 
• 1038924-00-3 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-3-methoxy-, 10-(1,1-dimethylethyl) ester 

Downstream Products

• 1204417-26-4 6-[[[2-[2-[(aminosulfonyl)methylamino]ethoxy] ethyl]methylamino]carbonyl]-13-cyclohexyl-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 1,1-dimethylethyl ester 
• 1204417-27-5 6-[[[2-[2-[(aminosulfonyl)methylamino]ethoxy]ethyl]methylamino]carbonyl]-13-cyclohexyl-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid 
• 1204416-98-7 C₃₂H₄₀N₄O₆S 
• 1204416-99-8 (19R)-2,19-methano-3,7:4,1-dimetheno-1H,11H-14,10,2,9,11,17-benzoxathiatetraazacyclodocosine-8,18(9H,15H)-dione 27-cyclohexyl-12,13,16,17,19,20-hexahydro-22-methoxy-11,17-dimethyl-10,10-dioxide 
• 1204417-00-4 (19S)-2,19-methano-3,7:4,1-dimetheno-1H,11H-14,10,2,9,11,17-benzoxathiatetraazacyclodocosine-8,18-(9H,15H)-dione 27-cyclohexyl-12,13,16,17,19,20-hexahydro-22-methoxy-11,17-dimethyl-10,10-dioxide 
• 1204416-97-6 2,19-methano-3,7:4,1-dimetheno-1H,11H-14,10,2,9,11,17-benzoxathiatetraazacyclodocosine-8,18(9H,15H)-dione, 27-cyclohexyl-12,13,16,17-tetrahydro-22-methoxy-11,17-dimethyl-, 10,10-dioxide 
• 1204417-28-6 C₃₅H₄₂N₆O₆S 

Relevant articles and documents

Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase

Structure-based macrocyclization of a 6-carboxylic acid indole chemotype has yielded potent and selective finger-loop inhibitors of the hepatitis C virus (HCV) NS5B polymerase. Lead optimization in conjunction with in vivo evaluation in rats identified several compounds showing (i) nanomolar potency in HCV replicon cells, (ii) limited toxicity and off-target activities, and (iii) encouraging preclinical pharmacokinetic profiles characterized by high liver distribution. This effort culminated in the identification of TMC647055 (10a), a nonzwitterionic 17-membered-ring macrocycle characterized by high affinity, long polymerase residence time, and broad genotypic coverage. In vitro results of the combination of 10a with the HCV protease inhibitor TMC435 (simeprevir) supported an evaluation of this combination in patients with regard to virus suppression and resistance emergence. In a phase 1b trial with HCV genotype 1-infected patients, 10a was considered to be safe and well-tolerated and demonstrated potent antiviral activity, which was further enhanced in a combination study with TMC435.

Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties

The concept of drug-likeness distills the physicochemical properties of small-molecule drugs to a set of rules. Macrocyclic drugs are known to break these rules. A structure-based macrocyclization strategy was applied to design new hepatitis C virus NS5B inhibitors with improved pharmacokinetic properties, exemplifying a rational strategy for overcoming the confines of standard drug-like chemical space . Copyright